Kamada Current Ratio 2012-2021 | KMDA

Kamada current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Kamada Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.18B $0.03B 6.86
2021-03-31 $0.18B $0.02B 7.97
2020-12-31 $0.18B $0.03B 7.13
2020-09-30 $0.18B $0.02B 7.53
2020-06-30 $0.18B $0.03B 5.79
2020-03-31 $0.17B $0.03B 6.55
2019-12-31 $0.14B $0.03B 4.39
2019-09-30 $0.13B $0.02B 6.14
2019-06-30 $0.13B $0.03B 4.74
2019-03-31 $0.11B $0.02B 5.29
2018-12-31 $0.11B $0.02B 4.71
2018-09-30 $0.09B $0.02B 4.86
2018-06-30 $0.10B $0.03B 3.95
2018-03-31 $0.10B $0.03B 3.47
2017-12-31 $0.10B $0.03B 3.30
2017-09-30 $0.09B $0.02B 3.71
2017-06-30 $0.08B $0.03B 2.85
2017-03-31 $0.07B $0.03B 2.82
2016-12-31 $0.08B $0.03B 2.83
2016-09-30 $0.07B $0.02B 3.90
2016-06-30 $0.08B $0.02B 3.55
2016-03-31 $0.09B $0.03B 3.11
2015-12-31 $0.08B $0.02B 3.51
2015-09-30 $0.09B $0.03B 2.88
2015-06-30 $0.09B $0.03B 3.19
2015-03-31 $0.09B $0.03B 3.29
2014-12-31 $0.10B $0.03B 3.14
2014-09-30 $0.10B $0.03B 3.32
2014-06-30 $0.11B $0.04B 3.16
2014-03-31 $0.12B $0.03B 3.41
2013-12-31 $0.12B $0.03B 3.61
2013-09-30 $0.12B $0.03B 4.42
2013-06-30 $0.12B $0.03B 4.19
2013-03-31 $0.07B $0.03B 2.21
2012-12-31 $0.07B $0.03B 2.39
2012-09-30 $0.07B $0.02B 2.81
2012-06-30 $0.00B 0.00
2012-03-31 $0.00B 0.00
2011-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.252B $0.133B
Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86